<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720418</url>
  </required_header>
  <id_info>
    <org_study_id>OXB-102-01</org_study_id>
    <nct_id>NCT03720418</nct_id>
  </id_info>
  <brief_title>Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease</brief_title>
  <acronym>SUNRISE-PD</acronym>
  <official_title>A Phase I/II Safety and Dose Evaluation Study of OXB-102 in Patients With Bilateral Idiopathic Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axovant Sciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oxford BioMedica</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Axovant Sciences Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consists of two parts. Part A will evaluate the safety and tolerability of
      multiple doses of OXB-102 (AXO-Lenti-PD) in patients with Parkinson's disease. Part B will
      assess the safety and efficacy of the selected dose of OXB-102 in patients with Parkinson's
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of two parts. Part A is an open-label dose-escalation phase in which
      patients are enrolled in cohorts and will receive one of approximately three escalating doses
      of OXB-102 (AXO-Lenti-PD). Part B is a randomized, double-blind phase in which patients will
      be randomized to either an active group receiving the selected dose from Part A, or to a
      control group receiving an imitation surgical procedure (ISP).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2018</start_date>
  <completion_date type="Anticipated">December 2031</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study Part A open-label and Study Part B randomized, double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of OXB-102-01 as measured by incidence of treatment emergent adverse events and serious adverse events</measure>
    <time_frame>3 months timepoint</time_frame>
    <description>Treatment emergent adverse events and serious adverse events will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, for severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of OXB-102-01 as measured by changes in clinical laboratory analysis</measure>
    <time_frame>3 months timepoint</time_frame>
    <description>Number of clinically significant changes in clinical laboratory analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of OXB-102-01 as measured by changes in vital signs</measure>
    <time_frame>3 months timepoint</time_frame>
    <description>Number of clinically significant changes in vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of OXB-102-01 as measured by changes in brain MRI findings</measure>
    <time_frame>3 months timepoint</time_frame>
    <description>Number of clinically significant changes in brain MRI findings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of OXB-102-01 as measured by changes in physical examination</measure>
    <time_frame>3 months timepoint</time_frame>
    <description>Number of clinically significant changes in physical examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in Unified Parkinson's Disease Rating Scale (UPDRS) scores compared to baseline in defined &quot;OFF&quot; and &quot;ON&quot; medication states</measure>
    <time_frame>6 months timepoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in motor fluctuations compared to baseline as assessed by patient diaries</measure>
    <time_frame>6 months timepoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in dyskinesia rating scale from baseline</measure>
    <time_frame>6 months timepoint</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>OXB-102 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OXB-102 Dose Level 1 Single Administration (Part A: open-label)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OXB-102 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OXB-102 Dose Level 2 Single Administration (Part A: open-label)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OXB-102 Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OXB-102 Dose Level 3 Single Administration (Part A: open-label)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OXB-102 Selected Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selected Dose of OXB-102 Single Administration (Part B: double-blind)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imitation Surgical Procedure</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>General anesthesia with bilateral skin incisions (Part B: double-blind)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OXB-102</intervention_name>
    <description>Neurosurgical delivery of OXB-102 (gene therapy) to the striatum</description>
    <arm_group_label>OXB-102 Dose Level 1</arm_group_label>
    <arm_group_label>OXB-102 Dose Level 2</arm_group_label>
    <arm_group_label>OXB-102 Dose Level 3</arm_group_label>
    <arm_group_label>OXB-102 Selected Dose</arm_group_label>
    <other_name>AXO-Lenti-PD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Imitation Surgical Procedure (ISP)</intervention_name>
    <description>Patients randomized to the control group in Part B will receive an ISP</description>
    <arm_group_label>Imitation Surgical Procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed with bilateral idiopathic PD

          2. Males/females between 30 and 70 years at the time of surgery

          3. Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) score of between 30 and 60
             in the &quot;OFF&quot; medication

          4. Presence of motor fluctuations and/or dyskinetic movement

          5. Candidate for surgical intervention

          6. Hoehn and Yahr (H&amp;Y) Stage 3 or 4 in the &quot;OFF&quot; medication state

          7. Stable dosing of PD medication, including L-DOPA, for four weeks prior to screening

          8. Levodopa equivalent daily dose (LEDD):

        at least 900 mg

        Exclusion Criteria:

          1. History of psychosis or current treatment with dopamine blocking agents and prior
             regular exposure to antipsychotic agents

          2. History of stereotactic or other surgery for the treatment of PD, including Deep Brain
             Stimulation (DBS)

          3. Participation in a prior cell or gene transfer therapy study

          4. Contraindications to use of anaesthesia

          5. Current or anticipated treatment with anticoagulant therapy or the use of
             anticoagulation therapy that cannot be temporarily stopped around the time of surgery

          6. Diagnosis of multiple system atrophy

          7. Abnormal MRI findings such as mega cisterna, septum pellucidum, signs of severe
             cortical or subcortical atrophy, brain tumours, vascular diseases, trauma or
             arteriovenous malformations

          8. Presence of dementia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Travis B Lewis, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Axovant Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Travis B Lewis, MD, PhD</last_name>
    <phone>1-646-593-8403</phone>
    <email>travis.lewis@axovant.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rizalyn Golnar</last_name>
    <phone>1 -646-495-5312</phone>
    <email>Rizalyn.Golnar@axovant.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Neurochirurgie, Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cambridge, Centre for Brain Repair</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0PY,</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The National Hospital for Neurology and Neurosurgery</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 16, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>OXB-102</keyword>
  <keyword>AXO-Lenti-PD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

